15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index; 86 of the 155 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care section summarizes clinical practice recommendations for managing diabetes in pregnancy, covering preconception care, glycemic targets, gestational diabetes, preexisting type 1/type 2 diabetes, preeclampsia prevention, and postpartum care. It is a guideline synthesis rather than a primary study, with recommendations graded by available evidence.
Key findings
- Preconception care should target A1C <6.5% (<48 mmol/mol) to reduce congenital anomalies, preeclampsia, macrosomia, and preterm birth; preconception care in preexisting diabetes was associated with lower A1C and reduced birth defects, preterm delivery, perinatal mortality, small-for-gestational-age births, and NICU admissions.
- Pregnancy glucose goals are fasting plasma glucose <95 mg/dL (<5.3 mmol/L) and either 1-h postprandial <140 mg/dL (<7.8 mmol/L) or 2-h postprandial <120 mg/dL (<6.7 mmol/L); A1C goal is <6% (<42 mmol/mol) if achievable without significant hypoglycemia, relaxed to <7% (<53 mmol/mol) if needed. CGM is recommended in type 1 diabetes pregnancy, with target sensor range 63–140 mg/dL (3.5–7.8 mmol/L) and TIR goal >70%.
- For GDM, lifestyle behavior change is essential and may suffice; insulin is preferred when medication is needed. Metformin and glyburide should not be first-line because both cross the placenta; 70–85% of people with GDM by Carpenter-Coustan criteria can manage with lifestyle alone, while glyburide and metformin failed adequate glycemic outcomes in 23% and 25–28% of participants, respectively.
- Postpartum, GDM history should be screened at 4–12 weeks with a 75-g OGTT; lifetime maternal diabetes risk is 50–60%, with a 10-fold increased risk of type 2 diabetes versus no GDM. Lifestyle intervention and metformin reduced progression to diabetes by 35% and 40%, respectively, over 10 years; insulin requirements are often roughly half prepregnancy levels initially postpartum, and one study found they were 34% lower.
Methods
- This is an ADA “Standards of Care in Diabetes—2024” clinical practice guideline section, produced by the ADA Professional Practice Committee, which updates recommendations annually or more frequently as warranted.
- It synthesizes evidence from observational studies, RCTs, systematic reviews, and meta-analyses; no new primary data collection or trial is reported.
- Recommendations are organized across preconception counseling, glycemic goals, glucose monitoring, GDM management, preexisting type 1 and type 2 diabetes, preeclampsia/aspirin, pregnancy drug considerations, and postpartum care.
Limitations
- The paper states there are no adequately powered randomized trials comparing different fasting and postmeal glycemic goals for preexisting diabetes in pregnancy; data are insufficient to support CGM in all people with type 2 diabetes or GDM; long-term safety data for offspring exposed to glyburide are not available; and there are no intervention trials in offspring of mothers with GDM.
- It also notes that the most appropriate hypoglycemia threshold in pregnancy has not been validated, and that observational preconception A1C data are confounded by other self-care behaviors.
- Evident from the text: several recommendations rely on expert opinion or limited evidence, including some graded E, and some management decisions are individualized because of insufficient data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
69 Valid · 3 Not valid · 30 Not checked · 1 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the presence of microvascular complications is associated with higher risk of disease progression and adverse pregnancy outcomes (22).”
What the sources say
- Supportedcites [22] Relph, 2021, Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis, PLoS Med source
The Discussion’s Main findings section reports greater risks of adverse maternal and offspring outcomes in pregnant women with preexisting diabetes and microvascular disease. The Results table on risk factors for progression also associates existing retinopathy and nephropathy with worsening or new-onset retinopathy during pregnancy. The claim is supported in this pregnancy-and-diabetes context. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There are insufficient data to support the use of CGM in all people with type 2 diabetes or GDM (53,54).”
What the sources say
- Not checked — no full text of the sourcecites [53] García-Moreno, 2022, Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials, Diabet Med source
- Partly supportedcites [54] Wyckoff, 2021, Time in range in pregnancy: is there a role?, Diabetes Spectr sourceExperimental — accuracy not yet measured
The section on trials in type 2 diabetes or GDM says that CGM outcomes data are far less robust, with no RCTs specifically studying type 2 diabetes in pregnancy and limited data for GDM. That supports caution about universal CGM use during pregnancy, but the source does not address all people with type 2 diabetes outside pregnancy, as the citing sentence could imply. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cost of CGM in pregnancies complicated by type 1 diabetes is offset by improved maternal and neonatal outcomes (52).”
What the sources say
- Supportedcites [52] Ahmed, 2021, The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial, CMAJ Open source
The Interpretation conclusion says that, for pregnant patients with type 1 diabetes, governments could pay up to $1372 for CGM devices and sensors without increasing overall costs compared with SMBG, while improving maternal and neonatal outcomes. The Abstract Interpretation attributes the cost balance in part to lower neonatal intensive care costs. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In studies of individuals without preexisting diabetes, increasing A1C levels within the normal range are associated with adverse outcomes (38).”
What the sources say
- Partly supportedcites [38] Ho, 2017, Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women, PLoS One sourceExperimental — accuracy not yet measured
The Discussion and Results (Table 1; page numbers unavailable) associate higher mid-pregnancy HbA1c with several adverse pregnancy outcomes among women without overt diabetes, including at levels below 6.0%. The study is limited to high-risk pregnant Taiwanese women with positive glucose-challenge screens, so it does not establish the claim for individuals generally; the Discussion also describes the overall risk pattern as J-shaped, not uniformly increasing. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observational studies in preexisting diabetes and pregnancy show the lowest rates of adverse fetal outcomes in association with A1C <6-6.5% (<42-48 mmol/mol) early in gestation (4-6,40).”
What the sources say
- Partly supportedcites [4] Jensen, 2009, Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
Table 1 and the Results show the lowest observed rate of serious adverse outcomes in the lowest peri-conceptional A1C category, <6.9%, among women with type 1 diabetes. The paper does not distinguish outcomes below 6–6.5% or establish that narrower range as the lowest-risk threshold; its conclusion supports a preconceptional A1C target of <7%. (LLM, conf=0.88)
- Partly supportedcites [5] Suhonen, 2000, Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus, Diabetologia sourceExperimental — accuracy not yet measured
The Results (p. 3) show the lowest observed major-malformation rate in the HbA1c <5.6% group, measured before 14 weeks of gestation. This supports an association between lower early-pregnancy HbA1c and fewer malformations, but the paper does not establish a 6–6.5% cutoff or assess adverse fetal outcomes broadly; its study population was women with Type I diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] Nielsen, 2006, HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes, Diabetes Care source
- Not checked — no full text of the sourcecites [40] Maresh, 2015, Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes, Diabetes Care source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
61 more claims · 35 with their cited sources checked
Create a free account to see all 103 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 1
Citations
Cites
Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect
Victora, C. G., Bahl, R., Barros, A. J. D., França, G. V. A., Horton, S., Krasevec, J., Murch, S., Sankar, M. J., Walker, N., & Rollins, N. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01024-7 · Cited by 8,040
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Weight Gain During Pregnancy: Reexamining the Guidelines
Rasmussen, K. M., & Yaktine, A. L. (2009) · Cited by 4,473
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10803 · Cited by 2,089
Metzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Research works printed but not linked: 2
- 2006, Dietary Reference Intakes: The Essential Guide to Nutrient Requirements
- Henderson JT , VescoKK, SengerCA, . Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality (Evidence Synthesis, no. 205). Rockville, MD, Agency for Healthcare Research and Quality. Accessed 17 October 2023. Available from https://www.ncbi.nlm.nih.gov/books/NBK574449/
Cited by
Items 201–225 of 225
Sodeify, R., Seyednazari, M. A., Dorosti, A. M., & Nourazarian, A. (2026) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-026-07070-x · Cited by 2
“The 2024 Standards of Care advocate CGM alongside blood glucose monitoring for GDM, as systematic reviews con fi rm 15 – 20% reductions in adverse outcomes with real-time adjustments [305, 306].”
Cohenshtam, O., Zung, A., Yu, A., King, H., Kotova, P., Gover, O., Samuel, I. M., Helman, S., WALKER, M. D., Ben‐Zvi, D., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06771-w
KamaliZonouzi, S., Semnani, F., Mahiny, D., & Arevalo, J. F. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-026-07290-5
“Gestational diabetes mellitus (GDM), a form of glucose intolerance that arises during pregnancy, affects approximately 14% of pregnancies worldwide and is associated with both immediate maternal and fetal complications and potential long-term microvascular effects [1 , 2].”
Nutritional Practices During the Transition to Motherhood: A Systematic Qualitative Review
Kokkinari, A., Dagla, M., Gourounti, K., et al. (2026) · Nursing Reports · doi:10.3390/nursrep16070234
Alrasheed, M. A., Alwhaibi, A. M., Alsultan, D., Alamri, R., Alsulami, L., Al-Anazi, F., & Mansy, W. (2026) · INQUIRY The Journal of Health Care Organization Provision and Financing · doi:10.1177/00469580261420718
Gojnić-Dugalić, M., Dugalić, S., Ivanović, K., Milinčić, M., & Macura, M. (2026) · Healthcare · doi:10.3390/healthcare14142204
Gestational diabetes mellitus: Bridging research gaps through a translational framework
Dey, B. K., Basak, M., Maity, S., Roy, S., Kar, A., Chowdhury, S., Roy, S. B., Roy, M., Sahana, P., & Bhattacharjee, R. (2026) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_30_26
Wang, Y., Li, S., Huang, F., Li, J., Lian, X., Huang, L., Wu, W., & Li, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1887259
“In contrast, implementation-related practice (3, 4, 10).”
InfluentialMendagudali, R. R., Patil, S. S., Kurle, R., & Rao, P. (2026) · Cureus · doi:10.7759/cureus.114230
“…known as Short Messaging Services (SMS), as well as more complex functionalities and applications as part of mobile phones or as independent wireless devices [6]. monitoring of plasma glucose, and is primarily delivered through traditional education approaches and face-to-face consultation [7,8].”
Glucagon-Like Peptide-1 Receptor Agonists Use Among Reproductive-Aged Women with Type 2 Diabetes
Bailey, S. C., Cameron, N. A., Batio, S., Wismer, G. A., Wolf, M. S., Wallia, A., Schauer, J. M., Gemkow, J. W., Eggleston, A., Tenfelde, S., et al. (2026) · Journal of Women s Health · doi:10.1177/15409996261478007
Godage, P., Giggins, O. M., Doyle, J., & Byrne, A. (2026) · Women s Health · doi:10.1177/17455057261473448 · Cited by 1
Venkatesh, K. K., Joseph, J. J., Headings, A., Gillespie, S. L., Garner, J., Brock, G. N., Seiber, E. E., Wu, J., Kutay, H., Parsons, J., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-122856
“44 Of note, we selected a haemoglobin A1c threshold of 6.5% as opposed to 6.0%, as the latter may result in more frequent episodes of hypoglycaemia and the risk of adverse pregnancy outcomes is similar at both thresholds.”
InfluentialSastypratiwi, H., Wah, T. Y., & Azzuhri, S. R. (2026) · International Seminar on Intelligent Technology and Its Applications · doi:10.1109/isitia71267.2026.11642408
Elizar, E., Nurmila, N., Putri, H. W. K., Kartinazahri, K., Pebryatie, E., & Nurrochmi, E. (2026) · Jurnal Medisci · doi:10.62885/medisci.v4i1.1241
“…to be inseparable from a standardized content-development process based on clinical guidelines, so that the information received by pregnant women aligned with the GDM prevention and management standards recommended by (Association, 2024) and the Indonesian Society of Endocrinology (PERKENI, 2021).”
Feng, J., Liu, S., Lai, R., Zhong, Z., Chen, Y., & Liang, W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898511
Geerts, I., Yu, C., Embo, N., & Benhalima, K. (2026) · BMC Medicine · doi:10.1186/s12916-026-05191-2
“…of GDM typically involves a multidisciplinary approach, including dietary counselling, promotion of physical activity, and self-monitoring of blood glucose (SMBG), in line with American Diabetes Association (ADA) recommendations (fasting 95 mg/dL, 1 h 140 mg/dL and 2 h 120 mg/dL) [8, 9] (Fig.”
Lang, E. M., Smith, D., Adorno, M., Giarratano, G., & Ramos, M. D. (2026) · Healthcare · doi:10.3390/healthcare14172779
“…of severe-range values, and explicit escalation protocols [15], and for diabetes it includes intrapartum glucose management, insulin protocols, and neonatal hypoglycemia surveillance, together with discharge education addressing the substantial lifetime risk of type 2 diabetes following GDM [8].”
Iriye, B. K., & Kamyar, M. (2026) · American Journal of Perinatology · doi:10.1055/a-2949-9626
Koçar, M., & Cigilli, O. B. (2026) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog53317
Ratchakom, P., Rosjan, S., Piumsomboon, T., Pongsamakthai, M., & Intharah, T. (2026) · IEEE Access · doi:10.1109/access.2026.3730820
“This agent is responsible for logging a blood glucose value and assessing whether it falls within the two-hour postprandial range of 60–120 mg/dL [44].”
Peng¹, H., Yang², H., Zhao², W., Qin¹, L., Yi³, J., & Jin¹, R. (2026) · BMC Pregnancy and Childbirth · doi:10.21203/rs.3.rs-10830936/v1
Oguzhanoglu, M. K., & Karacabey, S. (2026) · Anatolian Current Medical Journal · doi:10.38053/acmj.1957626
Wang, Y., Zheng, H., Yue, C., et al. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1902356
“GDM not only increases the risk of preeclampsia (PE), cesarean delivery, and postpartum T2DM in pregnant women, but may also lead to adverse pregnancy outcomes such as fetal malformations, fetal growth restriction, and has a profound impact on long-term metabolic health of the offspring (3, 4).”
Postpartum Initiation of GLP-1 Receptor Agonists Among Commercially Insured Women in the US
Cai, S.-T., Simon, K., Shanks, A. L., et al. (2026) · JAMA · doi:10.1001/jama.2026.16841
Rice, S. M., Buchanan, L., Calkins, M. W., Cucuzzella, M. T., Cywes, R., Devine, P. L., Kalamian, M., Kalayjian, T., Reynolds, D. B., & Westman, E. C. (2026) · Journal of Metabolic Health · doi:10.4102/jmh.v9i1.152
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S282-S294
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725801
- OpenAlex
- W4389560993
- Semantic Scholar
- 1f3e4a9c0ae2be86d5da282aa96908a6bda368a2
- Cited by
- 232
- References
- 147
- Citations by year
- 2026: 60 · 2025: 106 · 2024: 66
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- diabetes in pregnancy, gestational diabetes mellitus, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Female, Humans, Pregnancy, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.